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BACKGROUND AND PURPOSE
Anthocyanins are phytochemicals with reported vasoactive bioactivity. However, given their instability at neutral pH, they are
presumed to undergo significant degradation and subsequent biotransformation. The aim of the present study was to
establish the pharmacokinetics of the metabolites of cyanidin-3-glucoside (C3G), a widely consumed dietary phytochemical
with potential cardioprotective properties.
EXPERIMENTAL APPROACH
A 500 mg oral bolus dose of 6,8,10,3′,5′-13C5-C3G was fed to eight healthy male participants, followed by a 48 h collection
(0, 0.5, 1, 2, 4, 6, 24, 48 h) of blood, urine and faecal samples. Samples were analysed by HPLC-ESI-MS/MS with elimination
kinetics established using non-compartmental pharmacokinetic modelling.
KEY RESULTS
Seventeen 13C-labelled compounds were identified in the serum, including 13C5-C3G, its degradation products, protocatechuic
acid (PCA) and phloroglucinaldehyde (PGA), 13 metabolites of PCA and 1 metabolite derived from PGA. The maximal
concentrations of the phenolic metabolites (Cmax) ranged from 10 to 2000 nM, between 2 and 30 h (tmax) post-consumption,
with half-lives of elimination observed between 0.5 and 96 h. The major phenolic metabolites identified were hippuric acid
and ferulic acid, which peaked in the serum at approximately 16 and 8 h respectively.
CONCLUSIONS AND IMPLICATIONS
Anthocyanins are metabolized to a structurally diverse range of metabolites that exhibit dynamic kinetic profiles.
Understanding the elimination kinetics of these metabolites is key to the design of future studies examining their utility in
dietary interventions or as therapeutics for disease risk reduction.
Abbreviations
ADME, absorption, distribution, metabolism and elimination; BA, benzoic acid; C3G, cyanidin-3-glucoside; Cy,
cyanidin; GlcA, glucuronide; 4-HBAL, 4-hydroxybenzaldehyde; P3G, peonidin-3-glucoside; PCA, protocatechuic acid;
PGA, phloroglucinaldehyde; VA, vanillic acid
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Introduction
Despite the growing evidence for the cardioprotective
effects of dietary anthocyanins such as cyanidin-3-glucoside
(C3G) (Erdman et al., 2007; Mink et al., 2007; Cassidy et al.,
2011; 2013), the mechanisms involved remain poorly
defined due to a limited understanding of their bioavailabil-
ity and metabolism. Anthocyanins are reported to have low
bioavailability, with the majority of studies recording a
recovery of <1% of the ingested anthocyanin dose (Kay
et al., 2005; Manach et al., 2005; McGhie and Walton,
2007). Several previous human feeding studies have
explored the absorption, distribution, metabolism and
elimination (ADME) of anthocyanins; however, most studies
only reported conjugated derivatives [methyl, glucuronide
(GlcA), sulfate] of parent anthocyanins as the major
metabolites in the circulation post-consumption, with
maximum serum concentrations ranging from 1.4 to
547 nM, between 0.5 and 1.5 h (tmax) post-consumption
(Kay et al., 2004; Manach et al., 2005; McGhie and Walton,
2007).
A human study feeding blood orange juice suggested
that the phenolic acid degradation product, protocatechuic
acid (PCA), was a major metabolite of anthocyanins
(Vitaglione et al., 2007). In addition, a range of phenolic
acids, including vanillic acid (VA), syringic acid, caffeic
acid and ferulic acid, have been identified within human
serum, following the consumption of an anthocyanin-rich
elderberry extract (de Ferrars et al., 2014) and bilberry-
lingonberry puree (Nurmi et al., 2009). However, the
complex flavonoid and phenolic profile of the interventions
limited the ability to trace the metabolites back to their
source. Furthermore, in vitro and human studies indicate
that such phenolic acids undergo phase II conjugation
(Nardini et al., 2006; 2009; Woodward et al., 2011), suggest-
ing that anthocyanins can undergo extensive metabolism in
vivo. Recent evidence also suggests that the major metabo-
lites of anthocyanins are likely to be derived from bacterial
fermentation and absorption from the colon (McGhie and
Walton, 2007; Del Rio et al., 2010; Williamson and Clifford,
2010).
The extensive degradation and metabolism of anthocya-
nins was recently confirmed in our stable isotope-labelled
C3G feeding study in which the relative bioavailability of
C3G was established as 12.4 ± 1.4%, based on the recovery of
the 13C-label in the urine and breath (Czank et al., 2013),
suggesting that the extent of anthocyanin absorption and
metabolism had been previously underestimated. Further-
more, given the degradation, short t½ and low Cmax of the
parent anthocyanins, the observed cardiovascular benefits of
anthocyanin consumption (Erdman et al., 2007; Mink et al.,
2007; Cassidy et al., 2011; 2013) are probably the conse-
quence of the metabolites, which are present within the
circulation for significantly longer and at higher concentra-
tions than the parent anthocyanins.
The present study aimed to identify the unique pharma-
cokinetic profiles of each anthocyanin metabolite following
the consumption of a 500 mg oral bolus dose of 13C-labelled
C3G. The findings from this work will inform the design of
future clinical interventions and mechanistic studies explor-
ing the biological activity of anthocyanins.
Methods
Chemicals and reagents
A 13C-enriched anthocyanin, 6,8,10,3′,5′-13C5-C3G (herein
referred to as 13C5-C3G), containing 13C at three positions on
the A-ring and two positions on the B-ring of the anthocya-
nin (Figure 1) was synthesized as previously described (Zhang
et al., 2011). Unlabelled C3G and peonidin-3-glucoside (P3G)
were obtained from Extrasynthese (Genay, France) as analyti-
cal standards. HPLC-grade acetonitrile was purchased from
Fisher Scientific (Loughborough, UK). Phase II conjugates of
phenolic acids [PCA-3-GlcA, PCA-4-GlcA, vanillic acid (VA)-
4-GlcA, isoVA-3-GlcA, benzoic acid (BA)-4-GlcA, PCA-3-
sulfate, PCA-4-sulfate, VA-4-sulfate and isoVA-3-sulfate] were
synthesized at St Andrews University, as previously described
(Zhang et al., 2012). Strata-X™ solid phase extraction (SPE)
columns (6 mL, 500 mg), Kinetex pentafluorophenol (PFP)
HPLC column (2.6 μM, 100 × 4.6 mm) and SecurityGuard®
cartridges (PFP, 4.0 × 2.0 mm) were purchased from Phenom-
enex (Cheshire, UK). Bond Elute C18 (20 mL, 5 g) SPE
columns were from Agilent (Workingham, UK), and Discov-
ery® DSC-18 SPE columns (6 mL, 1 g), Acrodisc PTFE syringe
filters (0.45 μm, 13 mm) and all other chemicals were pur-
chased from Sigma-Aldrich (Dorset, UK).
Clinical design
A detailed description of the clinical design was previously
published (Czank et al., 2013). Briefly, a single 500 mg oral
bolus dose of isotopically labelled C3G (13C5-C3G) was fed to
eight healthy male participants (body mass index, 18.5–
30.5 kg·m–2; aged 18–45 years) after an overnight fast (>8 h).
Participants provided blood (baseline, 0.5, 1, 2, 4, 6, 24, 48 h),
urine (individual voids between 0 and 6 h, total voids
between 6–24 and 24–48 h), breath (baseline, 0.5, 1, 2, 4, 6,
24, 48 h) and faecal samples (all voids between 0–6, 6–24 and
24–48 h). The study was conducted at the Clinical Research
and Trials Unit at the University of East Anglia according to
the principles expressed in the Declaration of Helsinki and
was approved by the Cambridgeshire 3 Research Ethics Com-
mittee (REC ref: 10/H0306/42) and registered at clinicaltri-
als.gov as NCT01106729.
Figure 1
Structure of 6,8,10,3′,5′-13C5-cyanidin-3-glucoside.
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Sample extraction and analysis
Serum, urine and faecal samples were extracted by SPE and
analysed by HPLC-ESI-MS/MS as recently described (Czank
et al., 2013). The extraction efficiency was established as 87 ±
11% (coefficient of variation, CV; 6.8 ± 0.7%) for serum, 88 ±
18% (CV, 7.9 ± 0.8%) for urine and 81 ± 21% (CV, 14.1 ± 1.2%)
for faeces (n = 3 replicates for each analyte). Sample extracts
(5 μL) were injected onto a Kinetex PFP column (Phenom-
onex) and separated using an Agilent 1200 series HPLC with a
QTrap 4000 linear ion trap mass spectrometer (ABSciex, War-
rington, UK). The HPLC gradient consisted of 0.1% (v v−1)
formic acid in water (A) and 0.1% (v v−1) formic acid in
acetonitrile (B), with a flow rate of 1.5 mL·min−1 and gradient
consisting of 1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min,
10% B at 17 min, 12% B at 18.5 min, 12.5% B at 20 min, 30%
B at 24 min and 90% B at 25 min. Metabolite identification
was performed by multiple reaction monitoring (MRM) opti-
mized for the detection of pure standards with m/z of the
parent and daughter fragments adjusted to +2,+3,+5 amu to
allow identification of the 13C-labelled metabolites derived
from the B-ring, A-ring or the parent structure respectively.
Metabolites were confirmed on the basis of retention time
(using authentic and synthesized standards where possible)
and three or more ion transitions. The HPLC-ESI-MS/MS
method was validated for linearity and precision across all
metabolites. Six point standard curves ranging from 1.25 to
20 μM were constructed from analytical standards and
injected six times. The precision was established as 1.4–11.0%
and linearity of the standard curves was established as r2 =
0.991–1.000 (CV, 0.2%) across the identified metabolites.
Pharmacokinetic and data analysis
Pharmacokinetic modelling of metabolites in the serum was
performed with the PKSolver ‘add-on’ for Excel 2010 (Micro-
soft, Mountain View, CA, USA) (Zhang et al., 2010) using
non-compartmental analysis with the AUC calculated using
the trapezoidal rule. Pharmacokinetic parameters were estab-
lished for each individual analyte and presented as mean ±
SEM. Urine samples collected during the first 6 h post-bolus
were grouped together to the nearest hour time point (i.e.
samples were not pooled but individual concentrations were
averaged post-quantification) for graphical representation
and to calculate total cumulative recovery. The concentration
of metabolites was converted to amount recovered from urine
by accounting for the molecular weight of the individual
13C-labelled metabolites and the volume of the individual
participants void and averaged across participants. Recovery
of metabolites in the faeces was established from the molecu-
lar weight of the 13C-labelled metabolite and the weight of
the individual participants void adjusting for faecal water
content as previously described (Czank et al., 2013). Urine
and faecal recovery amounts are presented as mean ± SEM (n
= 8), unless otherwise stated.
Results
Metabolite identification
A total of 35 13C-labelled analytes (including the parent 13C5-
C3G) were identified in the serum, urine and faecal samples
collected over 48 h post-consumption. The metabolites
identified included the degradation products of C3G [PCA
and phloroglucinaldehyde (PGA)], phase I (dehydroxylation,
reduction) and phase II (methyl, sulfate, glycine and glucu-
ronyl) conjugates of C3G, PCA and PGA, and probable bac-
terial metabolites, including carboxylic, phenylacetic and
phenylpropenoic acids. Of the 35 analytes identified, six
metabolites (two isomers of cyanidin-glucuronide, methyl-
cyanidin-glucuronide and three isomers of methyl-cyanidin-
3-glucose-glucuronide; Table 1) were tentatively identified as
having a neutral loss of 176 m/z (GlcA) while sharing
common daughter ion transitions with C3G or P3G. The
remaining 29 metabolites [C3G, P3G, PCA, PGA, hydroxy-
benzoic acid, BA-4-GlcA, PCA-3-GlcA, PCA-4-GlcA, PCA-3-
sulfate, PCA-4-sulfate, VA, isoVA, VA-4-GlcA, isoVA-3-GlcA,
VA-4-sulfate, isoVA-3-sulfate, 4-hydroxyphenylacetic acid,
3,4-dihydroxyphenylacetic acid, 4-hydroxybenzaldehyde
(4-HBAL), 3,4-dihydroxybenzaldehyde, caffeic acid, ferulic
acid (both A- and B-ring derived), hippuric acid, 4-
methoxybenzaldehyde, 2-hydroxy-4-methoxybenzoic acid,
methyl vanillate and methyl-3,4-dihydroxybenzoate
(Table 1)] were confirmed by comparison of retention time
and MS/MS fragmentation patterns to that of pure standards.
Serum pharmacokinetics
In the serum sample, a total of 17 13C-labelled compounds,
comprising C3G, PCA, PGA, 13 derivatives of PCA and 1
derivative of PGA, were detected (Table 2; Figures 2 and 3).
The Cmax of the analytes ranged from 11 nM for PCA-3-GlcA
(Figure 2B) to 1962 nM for hippuric acid (Figure 3A), with tmax
between 1.8 h for C3G and 30.1 h for VA-sulfate (Table 2).
Elimination half-lives (t½) also ranged from 0.4 h for C3G to
96.5 ± 73.4 h for the A-ring-derived ferulic acid (Table 2).
PCA-3-GlcA was the least abundant metabolite present in
the serum, whereas hippuric acid was the most abundant
metabolite (Table 2).
C3G reached a maximum serum concentration of 141 nM
(Figure 2A), whereas its degradation products, PCA and PGA,
were present at 146 nM (Figure 2B) and 582 nM (Figure 3C),
respectively, with their tmax occurring 2–3 h later than that of
C3G (Table 2). The metabolites of PCA were the dominant
species detected in the serum, with hippuric acid, VA and the
B-ring-derived ferulic acid representing the most abundant
metabolites. Hippuric acid, PCA-sulfate and ferulic acid had
significantly longer elimination half-lives than PCA (Table 2).
Eight sulfated and glucuronidated forms of PCA and methyl-
ated PCA (VA) were identified within the serum (Figure 2B,C),
with the conjugations occurring at both the meta and the
para positions. Of these, VA-sulfate was present in the highest
concentration followed by PCA-4-GlcA and PCA-sulfate
(Table 2). In contrast, only PGA and one other A-ring-derived
metabolite were identified within the serum, namely ferulic
acid (Figure 3C; Table 2).
Urinary elimination
In the urine sample, 31 13C-labelled compounds were identi-
fied, comprising C3G, 7 methylated and glucuronidated con-
jugates of C3G and cyanidin (Cy), PCA, PGA, 19 derivatives
of PCA, and 2 derivatives of PGA (Table 3; Figures 4 and 5).
Maximum concentrations of C3G and its conjugated deriva-
tives were identified between 1 and 2 h post-consumption
(Figure 4A). PCA also reached maximum concentration at
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Table 1
HPLC-MS/MS identification (MRM) of 13C-labelled cyanidin-3-glucoside (C3G) and its metabolites in the serum, urine and faeces of healthy
volunteers (n = 8) after the consumption of 500 mg of 13C-labelled C3G
Metabolite
Compound identification Analytical standards
Rt (min)
MRM ion transitions
(m/z)a Location # 13Cb MS2 fragments (m/z)
Parent anthocyanins
Cyanidin-3-glucoside (C3G) 12.6 454/292, 246, 218, 133 Urine, serum, faeces +5 449/287, 241, 213, 128
Cyanidin-glucuronide 11.7 468/292 Urine +5 NA
Cyanidin-glucuronide 16.5 468/292 Urine +5 NA
Peonidin-3-glucoside 16.6 468/306 Urine +5 463/301
Methyl-cyanidin-glucuronide 16.7 482/306 Urine +5 NA
Methyl-C3G-glucuronide 5.7 644/306 Urine +5 NA
Methyl-C3G-glucuronide 8.0 644/306 Urine +5 NA
Methyl-C3G-glucuronide 9.6 644/306 Urine +5 NA
Degradants
Protocatechuic acid (PCA) 4.3 155/111, 93, 83 Urine, serum, faeces +2 153/109, 91, 81
Phloroglucinaldehyde 7.4 156/155, 128, 110, 86 Urine, serum, faeces +3 153/151, 125, 107, 83
Metabolites
3-Hydroxybenzoic acid 8.1 138/95, 67 Urine, faeces +2 136/93, 65
4-Hydroxybenzoic acid 6.5 138/95, 67 Urine, faeces +2 136/93, 65
Benzoic acid-4-glucuronide 3.0 317/175, 155, 113, 95 Urine, serum, faeces +2 315/175, 153, 113, 93
PCA-3-glucuronide 4.3 331/175, 155, 113, 111 Urine, serum, faeces +2 329/175, 153, 113, 109
PCA-4-glucuronide 3.3 331/175, 155, 113, 111 Urine, serum, faeces +2 329/175, 153, 113, 109
PCA-3-sulfate 6.5 235/191, 155, 111 Urine, serum, faeces +2 233/189, 153, 109, 97
PCA-4-sulfate 6.2 235/191, 155, 111 Urine, serum, faeces +2 233/189, 153, 109, 97
Vanillic acid (VA) 9.5 169/154, 125, 110 Urine, serum, faeces +2 167/152, 123,108
IsoVA 9.9 171/153, 127, 95 Urine, serum, faeces +2 169/151, 125, 93, 65
IsoVA-3-glucuronide 6.2 347/175, 171, 154, 113 Urine, serum, faeces +2 345/175, 169, 152, 113
VA-4-glucuronide 4.9 347/175, 171, 154, 113 Urine, serum, faeces +2 345/175, 169, 152, 113
IsoVA-3-sulfate 8.8 247/169, 154, 125, 110 Urine, serum, faeces +2 245/167, 152, 123, 108
VA-4-sulfate 8.6 247/169, 154, 125, 110 Urine, serum, faeces +2 245/167, 152, 123, 108
4-Hydroxyphenylacetic acid 6.8 154/125, 109, 95 Urine, faeces +2 152/123, 107, 93, 79
3,4-Dihydroxyphenylacetic acid 4.6 171/127, 111, 97 Urine, faeces +2 169/125, 109, 95
4-Hydroxybenzaldehyde 8.5 123/110, 94, 67 Urine, serum, faeces +2 121/108, 92, 65
3,4-Dihydroxybenzaldehyde 5.8 139/110, 94, 83 Urine, faeces +2 137/109, 92, 81
Caffeic acid 10.4 183/139, 110, 93 Faeces +2 181/137, 108, 91
Ferulic acid 18.8 195/180, 150, 136 Urine, serum, faeces +2 193/178, 148, 134
196/181, 151, 137 Urine, serum, faeces +3
Hippuric acid 6.3 179/136, 134, 79 Urine, serum, faeces +2 177/134 ,132, 77
4-Methoxybenzaldehyde 19.6 169/125, 110, 81 Faeces +2 167/123, 108, 79
2-Hydroxy-4-methoxybenzoic acid 20.1 155/94, 79, 65 Faeces +2 153/92,77, 63
156/95, 80, 66 Urine +3
Methyl vanillate 21.4 185/153, 125, 109 Faeces +2 183/151, 123, 107, 77
Methyl-3,4-dihydroxybenzoate 12.9 170/111, 93 Urine, serum, faeces +2 168/109, 91
aMass spectra fragments for 13C-labelled metabolites with +2, +3 and +5 m/z.
b+2, +3 and +5 m/z refer to metabolites derived from PCA, PGA and cyanidin respectively.
NA, no analytical standard available for confirmation.
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1–2 h (Figure 4B), whereas PGA reached its peak concentra-
tion in the urine considerably later (6–24 h) (Figure 5C;
Table 3). The phenolic metabolites were excreted in much
higher concentrations than the parent anthocyanins, ranging
from 24 nM for 3,4-dihydroxybenzaldehyde (Figure 5C) to
5417 nM for hippuric acid (Figure 5A), with peak excretions
observed between 6 and 24 h post-consumption (Table 3).
Recovery of faecal metabolites
A total of 28 13C-labelled compounds were detected in the
faeces, including C3G, PCA, PGA, 24 B-ring-derived metabo-
lites and 1 A-ring-derived metabolite (Table 4). B-ring-derived
ferulic acid was present at the highest concentration within
the faeces, with a maximum recovery of 2373.1 μg at 6–24 h
post-bolus, followed by the A-ring-derived ferulic acid
(469.7 μg) and PCA (360.9 μg; Table 4).
Discussion and conclusions
Interest in anthocyanins continues to grow as a result of
their reported cardiovascular activity (Mink et al., 2007;
Cassidy et al., 2011; 2013). We recently established that
anthocyanins are absorbed and metabolized to a greater
extent than had been previously reported (Miyazawa et al.,
1999; Kay et al., 2004; 2005; Garcia-Alonso et al., 2009). Spe-
cifically, using a 13C-labelled anthocyanin and isotope-ratio
mass spectrometry, we established that a substantial number
and amount of breakdown products and conjugates of C3G
were absorbed, metabolized and excreted; as represented by
the recovery of 12% of the initial dose of 13C within the urine
sample (Czank et al., 2013). The present study indicates that
the majority of the label is present in the circulation as lower
molecular weight 13C-labelled phenolic metabolites of the
parent C3G.
By utilizing the targeted labelling of the A- and B-rings of
C3G (Figure 1), the present study was able to confirm the
pharmacokinetics of the phenolic conjugates of anthocya-
nins through the identification of 13C5-, 13C3- and 13C2-derived
metabolites of the parent anthocyanin. This strategy allowed
for the establishment of pharmacokinetic profiles of 17
metabolites in the circulation as well as the elimination of 31
and 28 metabolites in the urine and faeces respectively. To
our knowledge, this diversity of anthocyanin metabolites has
not been demonstrated previously in humans.
Table 2
Serum pharmacokinetic profiles of cyanidin-3-glucoside (C3G), its degradation products and derived metabolites in humans after the consump-
tion of 500 mg 13C-labelled C3Ga
Metabolite nb Cmax (nM) tmax (h) t1/2 (h) AUC0-48 (nmol h L−1)
Parent anthocyanins
Cyanidin-3-glucoside 5 141 ± 70 1.8 ± 0.2 0.4 279 ± 170
Degradants
Protocatechuic acid (PCA) 8 146 ± 74 3.3 ± 0.7 9.9 ± 3.4 1377 ± 760
Phloroglucinaldehyde 4 582 ± 536 2.8 ± 1.1 NQ 7882 ± 7768
Protocatechuic acid derived
Benzoic acid-4-glucuronide 7 74 ± 20 10.9 ± 3.4 17.1 ± 3.0 1467 ± 489
Methyl-3,4-dihydroxybenzoate 8 12 ± 5 8.4 ± 5.7 21.6 ± 5.9 171 ± 70
PCA-3-glucuronide 5 11 ± 3 2.7 ± 1.0 18.0 ± 15.6 60 ± 38
PCA-4-glucuronide 8 68 ± 61 3.8 ± 0.8 19.4 ± 3.1 618 ± 489
PCA-sulfatesc 8 157 ± 116 11.4 ± 3.8 31.9 ± 19.1 1180 ± 349
Vanillic acid (VA) 2 1845 ± 838 12.5 ± 11.5 6.4 23 319 ± 20 650
IsoVA 1 195 2.0 NQ 189
VA-4-glucuronide 8 24 ± 4 4.8 ± 0.4 NQ 74 ± 11
IsoVA-3-glucuronide 8 35 ± 5 4.3 ± 0.6 1.6 ± 0.2 103 ± 13
VA-sulfatesc 4 430 ± 299 30.1 ± 11.4 NQ 10 689 ± 7751
4-Hydroxybenzaldehyde 7 667 ± 653 5.6 ± 3.1 17.9 ± 8.8 663 ± 505
Ferulic acid 7 827 ± 371 8.2 ± 4.1 21.4 ± 7.8 17 422 ± 11 054
Hippuric acid 8 1962 ± 1389 15.7 ± 4.1 95.6 ± 77.8 46 568 ± 30 311
Phloroglucinaldehyde derived
Ferulic acidd 6 87 ± 38 13.3 ± 7.9 96.5 ± 73.4 1816 ± 1054
aValues are expressed as mean ± SEM.
bMetabolite detected in n = number of participants.
cPCA-sulfate and VA-sulfate isomers could not be separated sufficiently by HPLC to allow individual quantitation and the values presented are
cumulative concentration of both isomers.
dAlternative isomers of ferulic acid include 2-hydroxy-4-methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic acid.
NQ, not quantifiable as compounds remained sufficiently above baseline at 48 h.
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C3G and seven methylated and glucuronidated conju-
gates of C3G or Cy were identified within the urine sample,
reaching cumulative concentrations of 763 nM at 1–2 h post-
bolus (Figure 4A), which is in accordance with the previous
studies (Kay et al., 2004; Manach et al., 2005; McGhie and
Walton, 2007). However, the parent anthocyanin only repre-
sented 2% of the total metabolites found in the circulation
and was only present for a relatively short period of time (t½,
0.4 h; Table 2), thus suggesting that anthocyanin bioactivity
is likely to be mediated by high concentrations of its phenolic
intermediates as opposed to the parent structure.
It is well established that C3G degrades to PCA and PGA
when incubated at neutral pH (Kay et al., 2009; Woodward
et al., 2009) and this is corroborated by the present data, as
PCA (tmax, 3.3 h; Figure 2B) and PGA (tmax, 2.8 h; Figure 3C)
were some of the earliest phenolic metabolites identified in
the circulation (Table 2). In the present study, PCA was
observed at maximum concentrations of 147 nM, thus sug-
gesting that it is not a major metabolite of anthocyanins. The
A-ring-derived degradation product, PGA, was present at con-
centrations greater than either C3G or PCA in the serum
(Table 2 and Figure 3C). However, it was not detected in urine
Figure 2
Serum pharmacokinetic profiles of (A) C3G, (B) PCA and its metabolites and (C) methylated PCA and its metabolites, in humans after the
consumption of 500 mg 13C5-C3G in eight healthy male participants. All data are mean ± SEM. C3G, cyanidin-3-glucoside; GlcA, glucuronide;
M34dhbz, methyl-3,4-dihydroxybenzoate; PCA, protocatechuic acid; VA, vanillic acid.
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at any appreciable concentration, suggesting that it
was further metabolized prior to elimination (Table 3 and
Figure 5C). Multiple phase II metabolites of PCA were
detected in early (from 0.5 h to 1 h) serum samples, suggest-
ing that the degradation of anthocyanins in vivo is swiftly
followed by further biotransformation.
Hippuric acid was identified as the major metabolite of
anthocyanins in the present study, reaching a maximum
concentration of 1962 nM in the serum (Table 2). Hippuric
acid has been speculated to be a common metabolite for
many flavonoids (Pero, 2010) but it is a challenging metabo-
lite to identify without the use of an isotope label due to its
high background levels derived from other dietary and
endogenous (i.e. protein metabolism and amino acid catabo-
lism) sources, where it is reported to reach 1–2 mM concen-
trations in human urine (Toromanovic´ et al., 2008; Pero,
2010). The detection of 13C2-labelled hippuric acid in the
present study indicates that PCA and its conjugates are likely
further metabolized to form BA, which is conjugated with
glycine to form hippuric acid, or alternatively, formed from
Figure 3
Serum pharmacokinetic profiles of (A) benzoic acid metabolites, (B) propenoic acid metabolites, and (C) A-ring-derived and aldehyde metabolites
of cyanidin-3-glucoside in humans after the consumption of 500 mg 13C5-C3G in eight healthy male participants. All data are mean ± SEM. BA,
benzoic acid; BAL, benzaldehyde; GlcA, glucuronide; PGA, phloroglucinaldehyde.
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Table 3
Urinary recovery of cyanidin-3-glucoside, its degradation products and derived metabolites in humans after the consumption of 500 mg
13C-labelled C3Ga
Metabolite nb
Maximum
concentration (nM)
Time at maximum
concentration (h)c
Total
recovery (μg)
Parent anthocyanin
Cyanidin-3-glucoside (C3G) 7 334 ± 145 1–2 120.0 ± 54.1
Cyanidin-glucuronided 5 88 ± 42 1–2 23.9 ± 11.3
Cyanidin-glucuronided 3 19 ± 7 1–2 12.2 ± 6.8
Peonidin-3-glucoside 7 76 ± 43 1–2 22.9 ± 10.6
Methyl-cyanidin-glucuronidee 5 206 ± 105 1–2 74.9 ± 36.0
Methyl-C3G-glucuronidee 4 6 ± 2 1–2 2.3 ± 1.1
Methyl-C3G-glucuronidee 4 14 ± 7 1–2 6.7 ± 3.7
Methyl-C3G-glucuronidee 5 20 ± 8 1–2 9.5 ± 5.5
Degradants
Protocatechuic acid (PCA) 8 337 ± 117 1–2 71.6 ± 20.9
Phloroglucinaldehyde 8 170 ± 42 6–24 66.7 ± 21.3
Protocatechuic acid derived
Hydroxybenzoic acidf 5 49 ± 11 1–2 13.2 ± 3.7
Vanillic acid (VA) 4 3412 ± 312 1–2 960.4 ± 350.0
IsoVA 4 212 ± 130 1–2 79.5 ± 54.2
Methyl-3,4-dihydroxybenzoate 8 108 ± 39 3–4 20.7 ± 8.0
Benzoic acid-4-glucuronide 7 129 ± 47 4–5 53.1 ± 18.1
PCA-3-glucuronide 8 301 ± 72 1–2 197.7 ± 41.2
PCA-4-glucuronide 8 233 ± 65 1–2 100.3 ± 30.2
PCA-3-sulfate 8 1112 ± 318 1–2 322.0 ± 87.3
PCA-4-sulfate 8 1244 ± 333 1–2 492.4 ± 193.0
VA-4-glucuronide 8 762 ± 124 4–5 618.4 ± 109.7
IsoVA-3-glucuronide 8 699 ± 90 5–6 526.8 ± 92.2
VA-4-sulfate 7 1682 ± 899 3–4 449.1 ± 112.4
IsoVA-3-sulfate 5 822 ± 557 3–4 183.2 ± 93.1
Hippuric acid 8 5417 ± 4906 6–24 2415.6 ± 2223.0
Ferulic acid 8 1839 ± 657 24–48 798.2 ± 295.7
4-Hydroxyphenylacetic acid 3 391 ± 113 4–5 50.0 ± 2.0
3,4-Dihydroxyphenylacetic acid 1 82 24–48 28.0
4-Hydroxybenzaldehyde 2 97 ± 94 5–6 10.0 ± 9.0
3,4-Dihydroxybenzaldehyde 6 24 ± 7 0–1 6.3 ± 2.6
Phloroglucinaldehyde derived
Ferulic acidg 8 474 ± 273 0–1 225.1 ± 175.3
2-Hydroxy-4-methoxybenzoic acid 1 172 3–4 64.6
aValues are expressed as mean ± SEM.
bMetabolites detected in n = number of participants.
cSamples were pooled across participants urine voids, for t = 0–1 h (n = 3), t = 1–2 h (n = 5), t = 2–3 h (n = 6), t = 3–4 h (n = 6), t = 4–5 h
(n = 4), t = 5–6 h (n = 8), t = 6–24 h (n = 8) and t = 24–48 h (n = 8).
dQuantified relative to C3G.
eQuantified relative to peonidin-3-glucoside.
fIncludes both isomers (3-hydroxybenzoic acid and 4-hydroxybenzoic acid).
gAlternative isomers of ferulic acid include 2-hydroxy-4-methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic acid.
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the alpha-oxidation and dehydroxylation of hydroxypheny-
lacetic acids (Mullen et al., 2008). This suggests that glycine
conjugation is a key metabolic process responsible for the
clearance of phenolic metabolites of C3G from the body.
VA, the methylated metabolite of PCA, was also present
in the serum in high concentrations (Table 2 and Figure 2C);
however, it was only identified in the serum in two partici-
pants. Sulfation appeared to be the preferential metabolic
process for the clearance of PCA, as PCA-sulfate (Figure 2B)
and VA-sulfate (Figure 2C) were detected in much higher
concentrations than their unconjugated or GlcA counter-
parts. This pattern of elimination of PCA metabolites in the
serum was mirrored in the urine samples, with VA detected
at the highest concentration, followed by meta and para
sulfated and glucuronidated conjugates of PCA and VA
(Table 3). Di-methylation of PCA was also observed by the
Figure 4
Urinary elimination profiles of (A) C3G and its metabolites, (B) PCA and its metabolites, and (C) methylated PCA and its metabolites in humans
after the consumption of 500 mg 13C5-C3G in eight healthy male participants. All data are mean ± SEM. C3G, cyanidin-3-glucoside; Cy, cyanidin;
GlcA, glucuronide; M34dhbz, methyl-3,4-dihydroxybenzoate; Me, methylated; P3G, peonidin-3-glucoside; PCA, protocatechuic acid; VA, vanillic
acid.
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presence of methyl-3,4-dihydroxybenzoate and methyl
vanillate; however, methyl vanillate was only detected in
the faeces (Table 4), suggesting that di-methylation of PCA
results in biliary elimination, or more likely, is a product
of microbial metabolism. Therefore, a primary route of
metabolism and subsequent elimination of C3G appears to
be through degradation to PCA, followed by rapid methyla-
tion of the catechol group to form VA, and subsequent
sulfate and GlcA conjugation, thus increasing its polarity
and elimination from the body. This finding is supported by
previous studies feeding catechin to rats and guinea pigs,
where unconjugated metabolites represented only 3.5–4.4%
of the recovered phenolic metabolites (Das and Griffiths,
1969). Minimal amounts of phase I metabolites of
PCA were also detected in this study, including 3,4-
dihydroxybenzaldehyde (Figure 5C) and hydroxybenzoic
acid (Figure 5A) within urine and 4-HBAL within serum
(Figure 3C) and urine (Figure 5C), suggesting that phase I
metabolism may not be a highly utilized pathway for antho-
cyanin metabolism.
Figure 5
Urinary elimination profiles of (A) benzoic acid metabolites, (B) propenoic acid metabolites, and (C) A-ring-derived and aldehyde metabolites of
cyanidin-3-glucoside in humans after the consumption of 500 mg 13C5-C3G in eight healthy male participants. All data are mean ± SEM. 4-HBAL,
4-hydroxybenzaldehyde; BA, benzoic acid; BAL, benzaldehyde; GlcA, glucuronide; PAA, phenylacetic acid; PGA, phloroglucinaldehyde.
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Many metabolites of PCA in the present study appeared
to follow biphasic serum kinetics, displaying an initial
serum peak between 0 and 5 h followed by a second peak
between 6 and 48 h (Figures 2 and 3). Biphasic absorption
or elimination of delphinidin-3-glucoside has previously
been reported in rats, with maximum plasma concentra-
tions reported at 15 and 60 min (Ichiyanagi et al., 2004) and
also within human studies feeding flavonoids, where isofla-
vonoids and metabolites including caffeic acid, ferulic acid
and ferulic acid-sulfate were reported to follow biphasic
plasma kinetic patterns (Anupongsanugool et al., 2005;
Wittemer et al., 2005; Azzini et al., 2007; Stalmach et al.,
2009; Rodriguez-Mateos et al., 2013). The biphasic profiles
most likely result from metabolism occurring in multiple
tissues, including the liver and at different sites within the
gastrointestinal tract.
The route of elimination of the A-ring-derived metabo-
lites is less clear. A total of three A-ring-derived metabolites
Table 4
Total faecal recovery of cyanidin-3-glucoside its degradation products and derived metabolites in humans between 0–6, 6–24 and 24–48 h after
the consumption of 500 mg 13C-labelled C3G
Metabolite
Recovery (μg)
0–6 ha 6–24 h 24–48 h
Parent anthocyanin
C3G ND 70.0b 19.6b
Degradants
Protocatechuic acid (PCA) ND 360.9 ± 278.1c 221.8 ± 134.9d
Phloroglucinaldehyde ND 2.1 ± 1.3e 111.3 ± 78.7f
Protocatechuic acid derived
Hydroxybenzoic acid ND ND 22.0 ± 11.6g
2,3-Dihydroxybenzoic acid ND ND 440.4 ± 381.8h
2-Hydroxy-4-methoxybenzoic acid ND 1.4b 273.3 ± 272.7h
Vanillic acid (VA) ND 54.7 ± 1.6h 49.3 ± 21.4g
IsoVA ND 11.0b 8.5b
Methyl-3,4-dihydroxybenzoate ND 166.6 ± 100.6g 92.4 ± 49.4f
Methyl vanillate ND 35.1b ND
Benzoic acid-4-glucuronide 1.5b 6.8 ± 3.0c 14.8 ± 8.0i
PCA-3-glucuronide ND 22.9 ± 22.0g 49.0b
PCA-4-glucuronide ND 16.1 ± 17.5 20.4 ± 16.2i
PCA-3-sulfate 0.1b 30.0 ± 27.7h 11.7 ± 10.5e
PCA-4-sulfate ND 23.0 ± 18.1g 12.0 ± 10.2g
VA-4-glucuronide 3.6b 3.3b 9.5 ± 7.9g
IsoVA-3-glucuronide 1.8b 1.3b 12.7 ± 10.9h
VA-4-sulfate 0.6b ND 69.0 ± 39.1g
IsoVA-3-sulfate ND 0.6 ± 0.3h 176.1 ± 174.7h
Hippuric acid ND 12.0 ± 11.4g 27.5 ± 27.4h
Caffeic acid ND 25.2b 354.6 ± 125.0h
Ferulic acid ND 2373.1 ± 2905.4e 1454.7 ± 1362.0f
4-Hydroxyphenylacetic acid ND 7.3b 55.4b
3,4-Dihydroxyphenylacetic acid 2.0b 10.1 ± 4.0e 12.8 ± 7.5c
4-Hydroxybenzaldehyde ND 0.8 ± 0.8h 0.1b
4-Methoxybenzaldehyde ND 20.7b ND
3,4-Dihydroxybenzaldehyde ND 3.4 ± 3.8h 5.1 ± 1.8i
Phloroglucinaldehyde derived
Ferulic acidj ND 469.7 ± 687.1h 240.8 ± 154.3c
aNumber of participants providing sample voids at 0–6 h n = 2; all participants provided voids for the remaining time points.
Values are expressed as mean ± SEM, where metabolites were detected in bn = 1, cn = 5, dn = 7, en = 4, fn = 6, gn = 3, hn = 2, in = 8 participants.
jAlternative isomers of ferulic acid include 2-hydroxy-4-methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic acid.
ND, not detected.
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were identified in the serum, urine and faecal samples (PGA,
2-hydroxy-4-methoxybenzoic acid and a compound puta-
tively identified as ferulic acid). The metabolite tentatively
identified as ferulic acid matched the molecular weight (+3),
fragmentation pattern and had a retention time similar to the
ferulic acid standard (Table 1); however, the exact structural
conformation of 13C3-ferulic acid cannot be established with
certainty, as other probable isomers could result from the
methylation of the A-ring hydroxyl to form either 2-hydroxy-
4-methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic
acid. We are not aware of previous studies reporting these
metabolites and more work is required to confirm their
exact structural identities. In addition, A-ring-derived 3,4-
dihydroxybenzaldehyde and methyl 3,4-dihydroxybenzoate
were tentatively identified within post-bolus samples;
however, due to their low concentrations, they were not
included in the present analyses. At present, little is known
about the metabolism of PGA and further studies are required
to delineate the mechanisms involved in its metabolism and
clearance.
Colonic metabolism has long been speculated to be a
major contributor to the overall metabolism of anthocyanins
(Williamson and Clifford, 2010; Cardona et al., 2013) and our
13C-labelled C3G study reported 32 ± 6% of the recovered
13C-label in faeces (Czank et al., 2013). It has been proposed
that phenylpropenoic acids arise from C3G as a result of
bacterial cleavage of the C-ring in the colon (Forester and
Waterhouse, 2008; Gonzalez-Barrio et al., 2011), which is
supported by the detection of caffeic acid and its methyl
metabolite, ferulic acid, within the faeces in the present
investigation. The absence of caffeic acid in the serum and
urine despite its abundance within the faeces (Table 4)
suggests that the catechol group of caffeic acid is rapidly
methylated to yield ferulic acid, either during intestinal
absorption, prior to entry into the systemic circulation or by
the liver. The rapid metabolism of caffeic acid has been
observed in previous phenolic acid intervention studies,
where caffeic acid is reported at significantly lower concen-
trations than its methyl, glucuronyl and sulfate conjugates
(Nardini et al., 2006). In addition, ferulic acid was detected
within the serum and urine samples within 4 h of consump-
tion, indicating that ferulic acid may, in part, be formed
proximal to the colon (i.e. the middle and lower small
intestine).
On the basis of the findings of this study, the metabolism
of anthocyanins can be summarized as undergoing multiple
biotransformations (Figure 6). The parent compound appears
to undergo methylation and glucuronidation to some extent;
however, it primarily undergoes degradation, followed by
significant phase II conjugation, particularly methylation
and sulfation. Given the early timing and high concentra-
tions of PCA and PGA observed in this study, it is clear that
C3G spontaneously degrades to PCA and PGA in the small
intestine and circulation; however, colonic metabolism is also
likely to play a significant role. Dehydroxylation by colonic
bacteria, to form hydroxybenzoic acid, followed by conjuga-
tion with glycine to form hippuric acid, appears to be the
definitive elimination pathway. Finally, the metabolism of
PGA to phenylpropenoic acids, which are similar to, or
include, ferulic acid, may be responsible for the detoxifica-
tion and elimination of PGA.
The biological activities of the parent anthocyanins
has been previously reported (Xu et al., 2004; Bell and
Gochenaur, 2006; Kim et al., 2006; Nizamutdinova et al.,
2009; Zhu et al., 2011); however, the activities of the phenolic
metabolites identified in the present study are relatively
unknown. Many of the metabolites identified share structural
similarities with known bioactives such as apocynin, an
inhibitor of NADPH oxidase (Kim et al., 2011), and salicylic
acid, known for its anti-inflammatory activity (Vane and
Botting, 2003). Of the limited information available for many
of the presently identified metabolites, PCA has been shown
to reduce vascular cell adhesion molecule-1 (VCAM-1)
protein and mRNA in TNF-α-induced mouse aortic endothe-
lial cells (Wang et al., 2010). In addition, plasma VCAM-1
levels were reduced in mice fed PCA (Wang et al., 2010),
whereas vanillic acid fed mice showed reductions in plasma
IL-6 (Kim et al., 2010). Moreover, in LPS-induced RAW 264.7
cells, PCA has been shown to suppress the production of
TNF-α, IL-1β, NO, PGE2 and the gene expression of NOS and
COX-2 (Min et al., 2010). Together, these studies suggest that
the bioactivity of anthocyanins is likely attributed to their
phenolic metabolites, which may have both vascular and
anti-inflammatory activity. However, a great deal of work
is required to confirm the bioactivities of the extensive
numbers of metabolites identified herein.
The major limitation of the presently employed analytical
methodology is its targeted approach, which relies on pure
standards and MRM for identification. This approach is
highly sensitive; however, it does not allow for the identifi-
cation of unknown/untargeted metabolites. Additional syn-
thesis of the speculated metabolites is necessary to confirm
their identities. In addition, alternative spectroscopy tech-
niques such as GC-MS/MS and high resolution time-of-flight
MS would aid in identifying further metabolites not captured
by the present methodology. As many of the metabolites did
not completely returned to baseline by 48 h, a longer blood,
urine and faecal sampling time may have increased the recov-
ery of metabolites. Despite these limitations, this human
study has demonstrated for the first time that a wide array of
metabolites are recovered by the described extraction and
detection methods and these data represent a considerable
advancement in our understanding of anthocyanin ADME.
In conclusion, the extensive number of anthocyanin
metabolites identified, the appearance of multiple peaks
across the 48 h time period and the wide range of their
elimination half-lives suggest that the clearance of anthocya-
nins involves multiple processes, including enterohepatic
recirculation, hepatic recycling and microbial metabolism,
with an extended period of intestinal absorption from both
the small and the large bowel. This study provides new
insights into the metabolism of anthocyanins, which
should inform the design of future clinical studies exploring
the bioactivity of these potentially important dietary
compounds.
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